EGCG for Hepatocellular Carcinoma Chemoprevention

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Cirrhosis, Liver

In brief

This phase II trial tests epigallocatechin gallate (EGCG) for its efficacy and safety in preventing development of hepatocellular carcinoma (HCC) in patients with liver cirrhosis.

Key facts

Study ID

NCT06015022

Run by

University of Texas Southwestern Medical Center

People needed

60

Starts

2024-09-01

Expected to finish

2028-08-31

Last updated by the study team

2025-09-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults (≥ 18 years-old)
• Clinically and/or histologically diagnosed cirrhosis
• No active hepatic decompensation
• No prior history of HCC
• Adequate hematologic, hepatic, and renal function
• Karnofsky performance status score ≥70
• Both sexes and all racial/ethnic groups will be considered
• FIB-4 index > 3.25
• High-risk PLSec at baseline
• Absence of HLA-B*35:01

You may not qualify if…

• Prior or ongoing use of EGCG
• History of adverse reaction to green tea products
• Severe obesity (BMI > 40 kg/m2)
• Active drinking
• EGCG treatment <4 weeks or <80% of planned regimen at the end of week 4
• HCC development during the study

Where it is running

• UT Southwestern — Dallas, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.